PathoCare Holdings, Inc. Accepts Third-Party Tender Offer Valuing the Company at $500 Million and Launches New Equity Round to Support Product Development
The $500 million valuation assigned to PathoCare Holdings, Inc. in connection with the tender offer was independently determined by Lehrer Financial (a nationally recognized economic and financial consulting firm based in Houston, Texas, with over forty years of experience providing high-precision business valuations). Lehrer Financial has built a reputation for analytical rigor and defensible methodologies across industries—including healthcare, banking, real estate, and emerging technologies.
The transaction was structured in response to shareholder interest in early liquidity and estate planning, and was designed to support the evolving needs of long-term investors. A private institutional investor acquired a portion of PathoCare Holdings' outstanding equity in a tender offer authorized by the company's board of directors.
'This tender offer reflects continued confidence in the long-term value and market potential of PathoCare's breakthrough diagnostics platform,' said L. Mychal Jefferson, Chairman of PathoCare Holdings. 'As we scale our technology, we remain committed to supporting the needs of our investors, while enabling mission-critical product development.'
In parallel with the tender offer, PathoCare Holdings is reviewing opening a new private equity financing round to raise up to $25 million from qualified institutional investors. The capital will be used to accelerate the development, engineering, and regulatory readiness of the company's flagship product—the PathoWand, a next-generation point-of-care diagnostic device utilizing Raman spectroscopy and artificial intelligence for real-time pathogen detection.
This initiative follows a prior $150 million venture investment, acquisition and recapitalization led by Hamershlag Private Capital Management Limited, that resulted in Hamershlag Private acquiring seventy percent (70%) and the original founders receiving thirty percent (30%) of the of the newly restructured and recapitalized company. This marks another major milestone in PathoCare's transformation from a research-stage venture to a commercial healthcare technology platform.
Lehrer Financial specializes in non-public company valuations, intellectual property analysis, and merger & acquisition consulting, with expertise extending into litigation support and medical economics. Their valuation process included a comprehensive review of PathoCare's intellectual property portfolio, operating models, industry forecasts, and growth trajectory within the diagnostic testing sector.
Lehrer's valuation is supported by robust market and financial analysis and is designed to meet the highest professional standards—providing a credible foundation for both private equity transactions and shareholder decisions. The firm's long-standing reputation for producing concise, defensible, and expert-backed assessments ensured that PathoCare's corporate valuation could stand up to scrutiny from institutional investors and strategic advisors alike.
About PathoCare Holdings, Inc.
PathoCare Holdings, Inc. is the investment and holding entity created to support venture funding and corporate development of PathoCare, LLC. The company oversees strategic partnerships, capital structuring, and growth planning to expand PathoCare's patented Raman spectroscopy-based diagnostic platform.
About PathoCare, LLC
PathoCare, LLC is a Houston-based diagnostics technology company leveraging Raman spectroscopy and adaptive AI to deliver accurate, programmable, and reusable point-of-care testing systems. Its patented platform enables rapid, non-invasive diagnostics for bacterial and viral respiratory infections without the need for chemical reagents or long lab processing times. The company is a leader in the Lab-on-a-Chip non-invasive Point of Care diagnostic tests. PathoCare's revolutionary Raman spectroscopy-based testing platform is underpinned by 17 patents.
About Hamershlag Private Capital Management, Limited
Hamershlag Private is a family investment office dedicated to investing in category defining companies and projects across industries and sectors. They provide long term, flexible capital with a unique ability to act quickly on impactful opportunities. They maintain a diversified portfolio, with a focus on disruptive technologies, climate impact, and emerging industries by cultivating extensive long-term relationships with other family offices and investment firms across asset classes. Hamershlag Private combines institutional infrastructure with core values of flexibility, creativity, and execution.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
Institutions Are Driving Ethereum's 'Comeback'
For a year, Ethereum, the second largest blockchain, has lived in the shadows of its competitors, as cryptocurrencies like bitcoin and solana jumped in price and dominated the conversation. Amid criticism from investors and some community members, ETH languished at levels below $1500 as recently as April. But on Monday ETH was near $3800, up 13% year-to-date, and analysts pointed to numerous signs of a turning point for the project. Some have pointed out that the momentum of the ecosystem has returned partially thanks to the explosion of stablecoins and tokenization on Ethereum. 'For institutions looking to get exposure, Ethereum is the primary on-chain option, leading in real-world asset (RWA) tokenization with $7.8 billion in tokenized assets, or nearly 60% of the total RWA market cap,' said Jake Koch-Gallup, a research analyst at Messari, to CoinDesk. As of the beginning of July 2025, Whales with addresses that hold between 1,000-10,000 in ETH have increased their holdings of the token, according to data from Glassnode. Collectively they hold about 14 million ETH units, up from roughly 12 million at the end of 2024. Vivek Raman, who founded Etherealize and spends his time speaking with institutions to market ETH as an asset class, believes that ETH should be seen like BTC as 'a store of value," comparing it to 'digital oil.' The layer-2 ecosystem, which are auxiliary blockchains atop of Ethereum used to transact for faster and cheaper, have appeared en masse over the past few years, and institutions have started to also build with them. JP Morgan recently announced they launched a proof-of-concept for tokenizing their deposits on Coinbase's Base chain, while Robinhood, the retail trading giant, shared its plans to build its own layer-2 with the Arbitrum stack. If it works, it could bring Ethereum's technology to an even broader mainstream audience and deepen its position as the backbone for a new generation of financial applications. Some believe layer-2 networks were taking away value from the Ethereum base layer and making user experience more disconnected, but Raman argues that institutions view them differently. According to Raman, the customizability of a layer-2 network is a plus for these institutions. 'You can be a landlord and get access to the liquidity of Ethereum,' said Raman in an interview. 'So the validation of the L2 ecosystem is now pretty undeniable.' Koch-Gallup, at Messari, believes that protocol changes that enhance the scaling of Ethereum as a base layer will position the network well for the future. 'A 100-1,000x throughput jump collapses gas fees, reopens the space for consumer-grade apps, and refutes the 'L2s are eating the L1' narrative,' he said. 'Concurrently, bigger blocks and more activity feed back into base-fee burn, tightening ETH's supply during periods of high demand.' Ethereum is also benefitting from the corporate treasury trend, with a growing number of companies adopting ETH as a strategic treasury asset. That is, not just for holding, but for staking to generate yield, signaling a shift from traditional treasury strategies, often limited to cash or bitcoin, to one that leverages Ethereum's staking rewards, programmability, and integration into DeFi and stablecoin ecosystems. SharpLink Gaming, a NASDAQ-listed sports betting firm, BitMine, and BitDigital, both crypto mining firms, have all shifted their crypto treasury strategies to this. 'SharpLink Gaming (SBET) saw its stock price [rise 412%] after announcing its ETH treasury strategy, showing there's a clear market appetite for publicly traded companies holding ETH on their balance sheets,' Koch-Gallup told CoinDesk. The company is chaired by Joseph Lubin, one of the founders of Ethereum. BitMine, which recently saw Wall Street personality Tom Lee join, also shared that it holds over 300,000 ETH in its treasury. 'Collectively, these trends suggest a deeper institutional re-rating of Ethereum, not just as infrastructure, but as a yield-bearing, balance-sheet-worthy asset and a directional bet on the future of on-chain finance,' Koch-Gallup said. Read more: The Node: Is Ether Back From the Dead?
Business Wire
18-07-2025
- Business Wire
PathoCare Holdings, Inc. Accepts Third-Party Tender Offer Valuing the Company at $500 Million and Launches New Equity Round to Support Product Development
HOUSTON--(BUSINESS WIRE)--PathoCare Holdings, Inc.—the parent company of medical diagnostics innovator PathoCare, LLC (a leader in the Lab-on-a-Chip non-invasive Point of Care diagnostics)—has developed a set of tests backed by a revolutionary Raman spectroscopy-based testing platform that is underpinned by 17 patents and adaptive AI. Today, the company announced that it has accepted a third-party tender offer involving the secondary purchase of shares from an early investor. While specific transaction details remain undisclosed, the agreement reflects a company valuation of $500 million. The $500 million valuation assigned to PathoCare Holdings, Inc. in connection with the tender offer was independently determined by Lehrer Financial (a nationally recognized economic and financial consulting firm based in Houston, Texas, with over forty years of experience providing high-precision business valuations). Lehrer Financial has built a reputation for analytical rigor and defensible methodologies across industries—including healthcare, banking, real estate, and emerging technologies. The transaction was structured in response to shareholder interest in early liquidity and estate planning, and was designed to support the evolving needs of long-term investors. A private institutional investor acquired a portion of PathoCare Holdings' outstanding equity in a tender offer authorized by the company's board of directors. 'This tender offer reflects continued confidence in the long-term value and market potential of PathoCare's breakthrough diagnostics platform,' said L. Mychal Jefferson, Chairman of PathoCare Holdings. 'As we scale our technology, we remain committed to supporting the needs of our investors, while enabling mission-critical product development.' In parallel with the tender offer, PathoCare Holdings is reviewing opening a new private equity financing round to raise up to $25 million from qualified institutional investors. The capital will be used to accelerate the development, engineering, and regulatory readiness of the company's flagship product—the PathoWand, a next-generation point-of-care diagnostic device utilizing Raman spectroscopy and artificial intelligence for real-time pathogen detection. This initiative follows a prior $150 million venture investment, acquisition and recapitalization led by Hamershlag Private Capital Management Limited, that resulted in Hamershlag Private acquiring seventy percent (70%) and the original founders receiving thirty percent (30%) of the of the newly restructured and recapitalized company. This marks another major milestone in PathoCare's transformation from a research-stage venture to a commercial healthcare technology platform. Lehrer Financial specializes in non-public company valuations, intellectual property analysis, and merger & acquisition consulting, with expertise extending into litigation support and medical economics. Their valuation process included a comprehensive review of PathoCare's intellectual property portfolio, operating models, industry forecasts, and growth trajectory within the diagnostic testing sector. Lehrer's valuation is supported by robust market and financial analysis and is designed to meet the highest professional standards—providing a credible foundation for both private equity transactions and shareholder decisions. The firm's long-standing reputation for producing concise, defensible, and expert-backed assessments ensured that PathoCare's corporate valuation could stand up to scrutiny from institutional investors and strategic advisors alike. About PathoCare Holdings, Inc. PathoCare Holdings, Inc. is the investment and holding entity created to support venture funding and corporate development of PathoCare, LLC. The company oversees strategic partnerships, capital structuring, and growth planning to expand PathoCare's patented Raman spectroscopy-based diagnostic platform. About PathoCare, LLC PathoCare, LLC is a Houston-based diagnostics technology company leveraging Raman spectroscopy and adaptive AI to deliver accurate, programmable, and reusable point-of-care testing systems. Its patented platform enables rapid, non-invasive diagnostics for bacterial and viral respiratory infections without the need for chemical reagents or long lab processing times. The company is a leader in the Lab-on-a-Chip non-invasive Point of Care diagnostic tests. PathoCare's revolutionary Raman spectroscopy-based testing platform is underpinned by 17 patents. About Hamershlag Private Capital Management, Limited Hamershlag Private is a family investment office dedicated to investing in category defining companies and projects across industries and sectors. They provide long term, flexible capital with a unique ability to act quickly on impactful opportunities. They maintain a diversified portfolio, with a focus on disruptive technologies, climate impact, and emerging industries by cultivating extensive long-term relationships with other family offices and investment firms across asset classes. Hamershlag Private combines institutional infrastructure with core values of flexibility, creativity, and execution.
Business Wire
08-07-2025
- Business Wire
908 Devices Launches VipIR, a 3-in-1 Handheld Analyzer for Field-Based Chemical Identification of Unknown Bulk Substances
BOSTON--(BUSINESS WIRE)-- 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces the launch of VipIR, a 3-in-1 handheld analyzer that sets a new standard for rapid and confident field-based chemical identification of unknown bulk solids and liquids, such as narcotics, explosives, and toxic chemicals. VipIR enables customs and border personnel and hazardous response teams to simplify workflows and eliminate guesswork, accelerating decision making on scene. VipIR is redefining chemical analysis at the point of need with its combination of lab-grade analytical technologies, sophisticated algorithms and a simple, smart workflow that provides one confident result. Share At the heart of VipIR is Smart Spectral Processing (SSP), a proprietary algorithm that actively integrates data from Raman spectroscopy and FTIR (Fourier Transform Infrared) spectroscopy for analysis of complex or mixed substances from just one sample. No repositioning or repeated sampling is required. SSP uses the results of one spectroscopy technology to refine or confirm the other spectroscopy technology, delivering a more accurate and reliable chemical identification of an unknown substance. 'VipIR is redefining chemical analysis at the point of need with its combination of lab-grade analytical technologies, sophisticated algorithms and a simple, smart workflow that provides one confident result,' said Kevin J. Knopp, CEO and Co-founder, 908 Devices. 'This new chemical analyzer reinforces our commitment to providing frontline teams with next-generation tools that deliver confident, reliable answers.' Other VipIR features include: An expansive library of over 39,000 chemical spectra including drugs, toxic industrial materials, chemical warfare agents, explosives, and common chemicals Unique SSP single sample interface integrates FTIR and Raman analysis; additional sampling methods include a flexible Raman probe and integrated vial holder Built-in Wi-Fi and cellular connectivity enable fast data uploads, streamlined reporting and fleet management via the 908 Devices' Team Leader app Rugged, lightweight design For more information about VipIR, visit About 908 Devices 908 Devices is revolutionizing chemical analysis with its simple handheld devices, addressing life-altering applications. The Company's devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers in vital health, safety and defense tech applications, addressing the fentanyl and illicit drug crisis, toxic carcinogen exposure, and global security threats. The Company designs and manufactures innovative products that bring together the power of complementary analytical technologies, software automation, and machine learning. For more information, visit Forward Looking Statements for 908 Devices This press release includes "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company's products. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management's current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under "Risk Factors" and elsewhere in the Company's filings with the Securities and Exchange Commission which are available on the SEC's website at Additional information will be made available in the Company's annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.
